Therefore, we demonstrated that Sema4A plays an important and dual role in SSc pathology, through the promotion inflammation and fibrosis, the two main features of SSc, suggesting that Sema4A might be a novel therapeutic target in SSc (manuscript under review). The gene discussed is SEMA4A; the disease is systemic sclerosis.